Inflammation‐driven variability in drug metabolism: Insights from voriconazole treatment of HSCT recipients
Sylvia D. Klomp, Martijn L. Manson, Henk‐Jan Guchelaar, Stefan Böhringer et autres
2 citationsBritish Journal of Clinical Pharmacology
Esther H.M. van Egmond
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
16Publications signalées
249Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
CAR-T cell therapy researchHematopoietic Stem Cell TransplantationImmune Cell Function and InteractionT-cell and B-cell ImmunologyAcute Lymphoblastic Leukemia research
Publications récentes
Selective lymphodepletion underlies the efficacy of horse anti-thymocyte globulin-based immunosuppressive therapy in aplastic anemia
Emma S. Pool, Cilia R. Pothast, Shannah M. Gennesse, Esther H.M. van Egmond et autres
1 citationHaematologica
Competitive Repopulation and Allo-Immunologic Pressure Determine Chimerism Kinetics after T Cell-Depleted Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion
Eva A. S. Koster, Peter A. von dem Borne, Peter van Balen, Esther H.M. van Egmond et autres
3 citationsTransplantation and Cellular Therapy
Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft
Floris C. Loeff, Esther H.M. van Egmond, Dirk Jan A. R. Moes, Charissa Wijnands et autres
11 citationsTransplant Immunology
CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II
Peter van Balen, Cornelis A.M. van Bergen, Simone A.P. van Luxemburg-Heijs, Wendy de Klerk et autres
30 citationsFrontiers in Immunology
Loss of the GPI‐anchor in B‐lymphoblastic leukemia by epigenetic downregulation of PIGH expression
Floris C. Loeff, Kevin Rijs, Esther H.M. van Egmond, Willem H. Zoutman et autres
5 citationsAmerican Journal of Hematology
Phase I/II clinical trial demonstrates feasibility, safety and effectivity of CMV-pp65-specific donor T-cells for the treatment of refractory CMV reactivation after allogeneic stem cell transplantation
Inge Jedema, Peter van Balen, Constantijn J.M. Halkes, Esther H.M. van Egmond et autres
0 citationsData Archiving and Networked Services (DANS)
Loss of Pigh Expression Frequently Results in a GPI-Negative Subclone Lacking CD52 Membrane Expression, Conferring Alemtuzumab Resistance to B Cell Acute Lymphoblastic Leukemia
Floris C. Loeff, Kevin Rijs, Willem H. Zoutman, Esther H.M. van Egmond et autres
0 citationsBlood
Effectivity Of Complement-Dependent Cytotoxicity Induced By Therapeutic Antibodies In Acute Lymphoblastic Leukemia Is Dictated By Antigen Expression Levels and Curtailed By Membrane-Bound Complement Regulatory Proteins
Floris C. Loeff, Esther H.M. van Egmond, Judith Olde Wolbers, J.H. Frederik Falkenburg et autres
0 citationsBlood
Rapid Re-expression of Retrovirally Introduced VersusEndogenous TCRs in Engineered T cells AfterAntigen-specific Stimulation
Marleen M. van Loenen, Renate S. Hagedoorn, Renate de Boer, Esther H.M. van Egmond et autres
13 citationsJournal of Immunotherapy
Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies
Marleen M. van Loenen, Renate de Boer, R.S. Hagedoorn, Esther H.M. van Egmond et autres
43 citationsHaematologica
T Cell Chimerism After T Cell Depleted Allogeneic Stem Cell Transplantation Is Influenced by Immunological Factors Including the Conditioning Regimen, CMV Serostatus and GvHD and Does Significantly Bias Overall Chimerism Status
Jessica C. Harskamp, Pim L. J. van der Heiden, Esther H.M. van Egmond, Sabrina A.J. Veld et autres
1 citationBlood
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.